Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy: Commentary

Emina H. Huang

doi:10.1007/s10350-007-9176-1

Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy: Commentary

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Pages (from-to)	269-270
Number of pages	2
Journal	Diseases of the Colon and Rectum
Volume	51
Issue number	2
DOIs	https://doi.org/10.1007/s10350-007-9176-1
State	Published - Feb 2008
Externally published	Yes

ASJC Scopus subject areas

Gastroenterology

Access to Document

10.1007/s10350-007-9176-1

Cite this

@article{64349833127040cdacbfc850be5e495e,

title = "Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy: Commentary",

author = "Huang, {Emina H.}",

year = "2008",

month = feb,

doi = "10.1007/s10350-007-9176-1",

language = "English (US)",

volume = "51",

pages = "269--270",

journal = "Diseases of the Colon and Rectum",

issn = "0012-3706",

publisher = "Lippincott Williams and Wilkins",

number = "2",

}

TY - JOUR

T1 - Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy

T2 - Commentary

AU - Huang, Emina H.

PY - 2008/2

Y1 - 2008/2

UR - http://www.scopus.com/inward/record.url?scp=38949141550&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38949141550&partnerID=8YFLogxK

U2 - 10.1007/s10350-007-9176-1

DO - 10.1007/s10350-007-9176-1

M3 - Comment/debate

AN - SCOPUS:38949141550

SN - 0012-3706

VL - 51

SP - 269

EP - 270

JO - Diseases of the Colon and Rectum

JF - Diseases of the Colon and Rectum

IS - 2

ER -

Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy: Commentary

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this